Adocia (STU:A89) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:A89 Adocia STU:A89
41 GF Score
Price €3.63
GF Value €0.82
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Adocia Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adocia  (STU:A89) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Adocia Cyclically Adjusted PS Ratio Related Terms


Adocia Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Adocia's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adocia Cyclically Adjusted PS Ratio Chart

Adocia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.73 1.72 5.15 2.43 3.59

Adocia Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.84 2.99 2.16 1.53 3.19

STU:A89 vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Adocia's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adocia Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adocia's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Adocia's Cyclically Adjusted PS Ratio falls into.


STU:A89
41GF Score
Adocia STU:A89
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adocia Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Adocia's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Adocia's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=0.082/120.8900*120.8900
=0.082

Current CPI (Dec25) = 120.8900.

Adocia Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 3.284 100.650 3.944
201712 2.837 101.850 3.367
201812 6.223 103.470 7.271
201912 0.309 104.980 0.356
202012 0.121 104.960 0.139
202112 0.205 107.850 0.230
202212 1.425 114.160 1.509
202312 0.194 118.390 0.198
202412 0.629 119.950 0.634
202512 0.082 120.890 0.082

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Adocia (STU:A89) Overvalued in 2026?

Based on GuruFocus' analysis, Adocia stock appears to be overvalued. The current stock price of €3.63 is trading 342.7% above its estimated GF Value™ of €0.82. GuruFocus considers Adocia to be Significantly Overvalued.

Key valuation signals for STU:A89:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.82 vs. price of €3.63 (342.7% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the STU:A89 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adocia Business Description

Other Exchanges 0QAI:UKADOC:France
Address 115 Avenue Lacassagne, Lyon, FRA, 69003
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
41GF Score

Get the complete analysis for STU:A89

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.63
Price
€0.82
GF Value